| First Author | Castro-Mollo M | Year | 2021 |
| Journal | Elife | Volume | 10 |
| PubMed ID | 34002695 | Mgi Jnum | J:307104 |
| Mgi Id | MGI:6712200 | Doi | 10.7554/eLife.68217 |
| Citation | Castro-Mollo M, et al. (2021) The hepcidin regulator erythroferrone is a new member of the erythropoiesis-iron-bone circuitry. Elife 10:e68217 |
| abstractText | Background: Erythroblast erythroferrone (ERFE) secretion inhibits hepcidin expression by sequestering several bone morphogenetic protein (BMP) family members to increase iron availability for erythropoiesis. Methods: To address whether ERFE functions also in bone and whether the mechanism of ERFE action in bone involves BMPs, we utilize the Erfe(-/-) mouse model as well as beta-thalassemic (Hbb(th3/+)) mice with systemic loss of ERFE expression. In additional, we employ comprehensive skeletal phenotyping analyses as well as functional assays in vitro to address mechanistically the function of ERFE in bone. Results: We report that ERFE expression in osteoblasts is higher compared with erythroblasts, is independent of erythropoietin, and functional in suppressing hepatocyte hepcidin expression. Erfe(-/-) mice display low-bone-mass arising from increased bone resorption despite a concomitant increase in bone formation. Consistently, Erfe(-/-) osteoblasts exhibit enhanced mineralization, Sost and Rankl expression, and BMP-mediated signaling ex vivo. The ERFE effect on osteoclasts is mediated through increased osteoblastic RANKL and sclerostin expression, increasing osteoclastogenesis in Erfe(-/-) mice. Importantly, Erfe loss in Hbb(th3/+) mice, a disease model with increased ERFE expression, triggers profound osteoclastic bone resorption and bone loss. Conclusions: Together, ERFE exerts an osteoprotective effect by modulating BMP signaling in osteoblasts, decreasing RANKL production to limit osteoclastogenesis, and prevents excessive bone loss during expanded erythropoiesis in beta-thalassemia. Funding: Y.Z.G. acknowledges the support of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 DK107670 to Y.Z.G. and DK095112 to R.F., S.R., and Y.Z.G.). M.Z. acknowledges the support of the National Institute on Aging (U19 AG60917) and NIDDK (R01 DK113627). T.Y. acknowledges the support of the National Institute on Aging (R01 AG71870). S.R. acknowledges the support of NIDDK (R01 DK090554) and Commonwealth Universal Research Enhancement (C.U.R.E.) Program Pennsylvania. |
